|
|
||||||||
One hundred fourteen Leishmania isolates from patients with different clinical forms of leishmaniasis in the State of Bahia, Brazil, were characterized by indirect radioimmune binding assay using specific monoclonal antibodies (serodeme analysis). Seventy-five of these isolates were also analyzed by enzyme electrophoresis, based on 11 enzyme loci; parasite species were compared, according to their characteristic zymodemes, to those of WHO Leishmania reference strains. All isolates could be classified into one of three species: Leishmania amazonensis (n = 40), L. braziliensis (n = 39) or L. chagasi (n = 35). The most interesting information obtained from this study is the realization that L. amazonensis is capable of producing a wide spectrum of disease in humans. Infection with this parasite was associated with many different clinical presentations, including cutaneous leishmaniasis [CL] (20/49 cases), mucocutaneous leishmaniasis [MCL] (5/13 cases) and, of special note, visceral leishmaniasis [VL] (11/46 cases), as well as four cases of post kala-azar dermal leishmaniasis [PKDL]. In situ tissue parasite characterization, by immunoperoxidase assay and employing anti-L. amazonensis amastigote monoclonal antibodies, confirmed the infection with this species in two cases of CL, one case of DCL, one case of MCL and one case of PKDL. Our results also demonstrate the difficulty of parasite differentiation based on clinical grounds, since at least L. amazonensis infection can be associated with all types of leishmanial diseases, and different Leishmania species may be associated with indistinguishable clinical presentations. Since leishmanial parasites may vary in their biological behavior or in their response to treatment, it is important that their identification be made by reliable methods.
This article has been cited by other articles:
![]() |
J. C. Fernandes Rodrigues, J. L. Concepcion, C. Rodrigues, A. Caldera, J. A. Urbina, and W. de Souza In Vitro Activities of ER-119884 and E5700, Two Potent Squalene Synthase Inhibitors, against Leishmania amazonensis: Antiproliferative, Biochemical, and Ultrastructural Effects Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4098 - 4114. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Alvar, P. Aparicio, A. Aseffa, M. Den Boer, C. Canavate, J.-P. Dedet, L. Gradoni, R. Ter Horst, R. Lopez-Velez, and J. Moreno The Relationship between Leishmaniasis and AIDS: the Second 10 Years Clin. Microbiol. Rev., April 1, 2008; 21(2): 334 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. Amato, F. F. Tuon, A. M. Siqueira, A. C. Nicodemo, and V. A. Neto Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review Am J Trop Med Hyg, August 1, 2007; 77(2): 266 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Clarencio, C. I. de Oliveira, G. Bomfim, M. M. Pompeu, M. J. Teixeira, T. C. Barbosa, S. Souza-Neto, E. M. Carvalho, C. Brodskyn, A. Barral, et al. Characterization of the T-Cell Receptor V{beta} Repertoire in the Human Immune Response against Leishmania Parasites. Infect. Immun., August 1, 2006; 74(8): 4757 - 4765. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. BOAVENTURA, V. CAFE, J. COSTA, F. OLIVEIRA, A. BAFICA, A. ROSATO, L. A. R. de FREITAS, C. BRODSKYN, M. BARRAL-NETTO, and A. BARRAL Concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am J Trop Med Hyg, August 1, 2006; 75(2): 267 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Pinheiro Jr., M. D. R. Hermida, M. P. Macedo, J. Mengel, A. Bafica, and W. L. C. dos-Santos Leishmania Infection Impairs {beta}1-Integrin Function and Chemokine Receptor Expression in Mononuclear Phagocytes Infect. Immun., July 1, 2006; 74(7): 3912 - 3921. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. ROTUREAU ECOLOGY OF THE LEISHMANIA SPECIES IN THE GUIANAN ECOREGION COMPLEX Am J Trop Med Hyg, January 1, 2006; 74(1): 81 - 96. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |